Teva v. Deva: Patent Infringement Battle Over ProAir HFA Albuterol Sulfate

Teva Branded Pharmaceutical Products has taken legal action against Deva Holding, accusing them of infringing on nine patents related to the asthma medication ProAir HFA. This legal challenge emerged after Deva applied for FDA approval to produce a generic version of the drug. The court is evaluating whether Teva’s claims present an actual controversy justifying a declaratory judgment. The outcome could impact generic drug competition significantly.